Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious ...
cash

Novartis ist Top-Pick der Deutschen Bank

Die Aktie von Novartis steigt, nachdem die Deutsche Bank die Basler als Top-Pick im europäischen Pharmasektor ausgerufen hat.
FiercePharma

Novartis links music and science in corporate campaign tied to Eurovision sponsorship

A Big Pharma may seem like an incongruous choice of sponsor for a global music competition, but a new campaign from Novartis suggests that its work actually has plenty in common with the 2025 ...

Novartis Pharma AG: Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren's disease

Designation based on clinical evidence supporting potential of ianalumab in Sjögren's disease, including phase III trials1Distinction expedites development and review of treatments for serious conditi ...